Status:
COMPLETED
Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis
Lead Sponsor:
Dattoli Cancer Center and Brachytherapy Research Institute
Collaborating Sponsors:
Sanofi
Conditions:
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation
Eligibility:
MALE
45-80 years
Brief Summary
In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the...
Eligibility Criteria
Inclusion
- Males age 45-80 years
- Diagnosis of prostate cancer
- Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation
- Baseline AUA score\< or =12
- May be on antiandrogenand/or alpha reductase therapy
- Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -
Exclusion
- History of insulin-dependent diabetes
- Uncontrolled hypertention
- History of symptomtic hypotension (including syncope and dizziness)
- Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention
- Pre-existing prostatitis either continuous or intermittent
- Concurrent use of any other anticholinergics
- previous or concurrent usage of LHRH agonist
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
End Date :
November 1 2005
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00264017
Start Date
November 1 2005
End Date
November 1 2005
Last Update
December 12 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dattoli Cancer Center and Brachytherapy Research Institute
Sarasota, Florida, United States, 34237